Circulating levels of vascular endothelial growth factor A and its soluble receptor in patients with biopsy-proven nonalcoholic fatty liver disease

Archives of Medical Research

Volumn 42, Issue 1, 2011, Pages 38-43

  Yilmaz, Yusuf ^a   Yonal, Oya ^a   Kurt, Ramazan ^a   Alahdab, Yesim Ozen ^a   Ozdogan, Osman ^a   Celikel, Cigdem Ataizi ^a   Ulukaya, Engin ^b   Imeryuz, Nese ^a   Kalayci, Cem ^a   Avsar, Erol ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b ULUDAG UNIVERSITY   (Turkey)

Author keywords

Enzyme linked immunosorbent assay; Liver fibrosis; Nonalcoholic fatty liver disease; Steatohepatitis; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PROTEIN BLOOD LEVEL;

ADULT; BIOPSY; FATTY LIVER; FEMALE; HUMANS; LIVER; MALE; MIDDLE AGED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 79952084700     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2010.12.001     Document Type: Article

References (31)

1. Erickson S.K. Nonalcoholic fatty liver disease. J Lipid Res 2009, 50:S412-S416.
2. Sass D.A., Chang P., Chopra K.B. Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci 2005, 50:171-180.
3. Almeda-Valdés P., Cuevas-Ramos D., Aguilar-Salinas C.A. Metabolic syndrome and non-alcoholic fatty liver disease. Ann Hepatol 2009, 8:S18-S24.
4. Byrne C.D., Olufadi R., Bruce K.D., et al. Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci 2009, 116:539-564.
5. Grønbaek H., Thomsen K.L., Rungby J., et al. Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes. Expert Rev Gastroenterol Hepatol 2008, 2:705-711.
6. Yilmaz Y., Ulukaya E., Gul O.O., et al. Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease. Clin Biochem 2009, 42:802-807.
7. Sung H.K., Michael I.P., Nagy A. Multifaceted role of vascular endothelial growth factor signaling in adult tissue physiology: an emerging concept with clinical implications. Curr Opin Hematol 2010, 17:206-212.
8. Watada H. Role of VEGF-A in pancreatic beta cells. Endocr J 2010, 57:185-191.
9. Brissova M., Shostak A., Shiota M., et al. Pancreatic islet production of vascular endothelial growth factor-a is essential for islet vascularization, revascularization, and function. Diabetes 2006, 55:2974-2985.
10. Makino N., Maeda T., Sugano M., et al. High serum TNF-alpha level in type 2 diabetic patients with microangiopathy is associated with eNOS down-regulation and apoptosis in endothelial cells. J Diabetes Complications 2005, 19:347-355.
11. Lim H.S., Blann A.D., Chong A.Y., et al. Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention. Diabetes Care 2004, 27:2918-2924.
12. Barylski M., Kowalczyk E., Banach M., et al. Plasma total antioxidant activity in comparison with plasma NO and VEGF levels in patients with metabolic syndrome. Angiology 2009, 60:87-92.
13. Wada H., Satoh N., Kitaoka S., et al. Soluble VEGF receptor-2 is increased in sera of subjects with metabolic syndrome in association with insulin resistance. Atherosclerosis 2010, 208:512-517.
14. Amarapurkar A.D., Amarapurkar D.N., Vibhav S., et al. Angiogenesis in chronic liver disease. Ann Hepatol 2007, 6:170-173.
15. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
16. Stuttfeld E., Ballmer-Hofer K. Structure and function of VEGF receptors. IUBMB Life 2009, 61:915-922.
17. LeCouter J., Moritz D.R., Li B., et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 2003, 299:890-893.
18. American College of Endocrinology and American Diabetes Association Consensus statement on inpatient diabetes and glycemic control. Diabetes Care 2006, 29:1955-1962. ACE/ADA Task Force on Inpatient Diabetes.
19. Grundy S.M., Brewer H.B., Cleeman J.I., et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433-438.
20. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
21. Belgore F.M., Blann A.D., Li-Saw-Hee F.L., et al. Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension. Am J Cardiol 2001, 87:805-807.
22. Belgore F.M., Lip G.Y., Blann A.D. Successful therapy reduces levels of vascular endothelial growth factor (VEGF) in patients with hypertension and patients with hypercholesterolemia. Atherosclerosis 2000, 151:599.
23. Blann A.D., Belgore F.M., Constans J., et al. Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. Am J Cardiol 2001, 87:1160-1163.
24. Lann D., LeRoith D. Insulin resistance as the underlying cause for the metabolic syndrome. Med Clin North Am 2007, 91:1063-1077.
25. Yoshiji H., Kuriyama S., Yoshii J., et al. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 2003, 52:1347-1354.
26. Cao Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal 2009, 2:re1.
27. Hemmeryckx B., van Bree R., Van Hoef B., et al. Adverse adipose phenotype and hyperinsulinemia in gravid mice deficient in placental growth factor. Endocrinology 2008, 149:2176-2183.
28. Jaroszewicz J., Januszkiewicz M., Flisiak R., et al. Circulating vascular endothelial growth factor and its soluble receptors in patients with liver cirrhosis: possible association with hepatic function impairment. Cytokine 2008, 44:14-17.
29. Sandhofer A., Tatarczyk T., Kirchmair R., et al. Are plasma VEGF and its soluble receptor sFlt-1 atherogenic risk factors? Cross-sectional data from the SAPHIR study. Atherosclerosis 2009, 206:265-269.
30. Emanuele E. Is biopsy always necessary? Toward a clinico-laboratory approach for diagnosing nonalcoholic steatohepatitis in obesity. Hepatology 2008, 48:2086-2087.
31. Yilmaz Y., Dolar E. Biomarkers for noninvasive biochemical diagnosis of nonalcoholic steatohepatitis: tools or decorations?. World J Gastroenterol 2009, 15:4346-4347.